‘Predicated on our study of the info, we can’t ensure that this expectation can be necessarily justified, given the number and quality of the variability we saw in the drug approval procedure,’ he said. Other authors on the study include Jenerius A. Aminawung, M.D., Nilay D. Shah, and Harlan M. Krumholz, M.D. The scholarly study was funded partly by the Pew Charitable Trusts. JAMA doi: 10.1001/jama.2013.282034.. All FDA drug approvals not created equal Many individuals and physicians assume that the safety and effectiveness of newly accepted drugs is well understood by the federal Food and Drug Administration – but a fresh study by researchers at Yale College of Medicine shows that the clinical trials used by the FDA to approve brand-new medicines between 2005 and 2012 vary widely within their thoroughness.The AES provides a lot more than $800,000 to support analysis teaching grants for clinicians, research grants and pre – and post-doctoral study and training fellowships. Each year, AES clinical and fundamental science fellowship awardees are chosen for their novel approaches to epilepsy care and research innovations that can help lead to new therapies and raise the knowledge of epilepsy. Offering early-career awards is normally central to the mission of AES, said Elson Therefore, M.D., AES president. As our Society functions to deepen understanding of the underlying mechanisms of epilepsy and stimulate improvements and new advancements in epilepsy treatment, it is critical that we help another generation of epilepsy research leaders to release and establish their professions.